Using a CRC mouse model, we demonstrated that the CAR-T cells engineered to secrete the BsAb PD-1-TREM2 scFv exhibited stronger anti-tumor potential than conventional CAR-T cells and CAR-T cells secreting PD-1 scFv alone. This evidence concerns the gene TREM2 and neoplasm.